This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods
by Ryan McQueeney
On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including Gilead's acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon's changes to Whole Foods stores.
Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval
by Zacks Equity Research
Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).
Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update
by Arpita Dutt
It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
by Ryan McQueeney
The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.
Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences
by Zacks Equity Research
Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
by Zacks Equity Research
Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
Gilead (GILD) Up 2.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
by Zacks Equity Research
Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.
Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
by Ryan McQueeney
Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
Amgen Presents New Repatha Analysis from FOURIER Study
by Zacks Equity Research
Amgen's (AMGN) new analysis from FOURIER study on Repatha showed that there was a strong progressive relationship between lower levels of bad cholesterol and a lower risk of cardiovascular events rates.
Company News For August 29, 2017
by Zacks Equity Research
Companies in the news are: EXPE,BIIB,GILD,KITE,JNJ
5 Top ROE Stocks to Buy as Hurricane Harvey Wreaks Havoc
by Supriyo Bose
ROE helps investors distinguish between profit-generating companies from profit burners and is useful for determining the financial health of a company.
Roche's Gazyva Gets Priority Review for Follicular Lymphoma
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.
Novartis Announces Positive Data on Cardiovascular Drug
by Zacks Equity Research
Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).
Why Did Kite Pharma (KITE) Stock Skyrocket Today?
by Benjamin Rains
Shares of cancer treatment drug maker Kite Pharma (KITE) soared on Monday morning after Gilead Sciences (GILD) officially announced it would purchase the company for a substantial premium.
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AstraZeneca (AZN) drug Faslodex receives FDA approval for a label extension for Faslodex in the first-line monotherapy setting for the treatment of advanced breast cancer.
Will Endo (ENDP) Continue to Disappoint Investors in 2017?
by Zacks Equity Research
Endo (ENDP) a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, is under significant pressure due to intensifying consortium pricing pressures and additional competitive entrants and product discontinuations.
Novartis (NVS) Receives EC Approval for Breast Cancer Drug
by Zacks Equity Research
Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.
Top Ranked Income Stocks to Buy for August 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, August 24th:
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
by Zacks Equity Research
Pfizer, Inc. (PFE) and six international cancer research groups are collaborating on a combination study to explore the use of Ibrance for first-line treatment of advanced breast cancer.
Are Glaxo's Successful New Drugs Enough to Drive Growth?
by Zacks Equity Research
Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked.
Alkermes Initiates Rolling Submission of Depression Drug
by Zacks Equity Research
Alkermes (ALKS) initiated the rolling submission of a New Drug Application (NDA) to the FDA for pipeline candidate ALKS 5461 for major depressive disorder.